SILO · Silo Pharma, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $18.0K | - | $18.0K | $18.0K | $18.0K | - | $18.0K | $18.0K | $18.0K | - |
| Cost of Revenue | $20.7K | - | $20.7K | $1.5K | $1.5K | - | $1.5K | $1.5K | $1.5K | - |
| Gross Profit | ($2.7K) | - | ($2.7K) | $16.6K | $16.6K | - | $16.6K | $16.6K | $16.6K | - |
| R&D | $1.01M | - | $543.6K | $717.2K | $594.0K | - | $517.5K | $392.8K | $318.2K | - |
| SG&A | - | - | - | - | - | - | - | $50.6K | $64.4K | - |
| Total Operating Expenses | $1.59M | - | $1.15M | $1.27M | $1.11M | - | $1.03M | $1.02M | $896.1K | - |
| D&A | - | - | - | - | - | - | - | - | - | - |
| Operating Income | ($1.59M) | - | ($1.15M) | ($1.25M) | ($1.09M) | - | ($1.01M) | ($1.00M) | ($879.5K) | - |
| Interest Expense | $3.4K | - | $886 | $1.6K | $1.9K | - | $1.1K | $1.9K | $1.9K | - |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($1.65M) | - | ($1.11M) | ($1.20M) | ($1.03M) | - | ($928.8K) | ($931.8K) | ($801.7K) | - |
| EPS - Basic | ($1.80) | - | ($1.80) | ($2.85) | ($3.45) | - | ($3.30) | ($4.65) | ($4.20) | - |
| EPS - Diluted | ($1.80) | - | ($1.80) | ($2.85) | ($3.45) | - | ($3.30) | ($4.65) | ($4.20) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $3.90M | $4.75M | $3.92M | $4.33M | $3.14M | $3.91M | $4.86M | $4.51M | $2.67M | $3.52M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | - | - | - | - | - | - | - | - | - | - |
| Current Assets | $6.80M | $7.39M | $6.16M | $6.37M | $5.60M | $7.11M | $8.26M | $7.73M | $6.88M | $7.68M |
| Total Assets | $7.02M | $7.61M | $6.38M | $6.65M | $5.90M | $7.41M | $8.57M | $8.04M | $6.94M | $7.75M |
| Current Liabilities | $704.8K | $650.2K | $708.3K | $1.05M | $1.19M | $1.66M | $1.04M | $1.32M | $873.7K | $775.6K |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $1.34M | $1.30M | $1.38M | $1.74M | $1.89M | $2.38M | $1.78M | $2.08M | $1.65M | $1.57M |
| Stockholders' Equity | $5.68M | $6.31M | $5.01M | $4.92M | $4.01M | $5.03M | $6.78M | $5.96M | $5.29M | $6.18M |
| Retained Earnings | ($21.14M) | ($19.49M) | ($18.61M) | ($17.50M) | ($16.30M) | ($15.26M) | ($13.53M) | ($12.61M) | ($11.67M) | ($10.87M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($822.6K) | - | - | - | ($1.64M) | - | - | - | ($838.2K) | - |
| Investing Cash Flow | ($23.6K) | - | - | - | $871.4K | - | - | - | $97.6K | - |
| Financing Cash Flow | - | - | - | - | - | - | - | - | ($115.5K) | - |
| CapEx | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | -14.8% | - | -14.8% | 91.9% | 91.9% | - | 91.9% | 91.9% | 91.9% | - |
| Operating margin | -8846.4% | - | -6388.2% | -6926.8% | -6069.7% | - | -5603.6% | -5563.2% | -4879.1% | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | -9137.5% | - | -6160.5% | -6681.2% | -5721.9% | - | -5152.9% | -5169.4% | -4447.3% | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | 5621.1% | - | 3015.9% | 3979.2% | 3295.0% | - | 2871.3% | 2179.3% | 1765.4% | - |
| SG&A / Revenue | - | - | - | - | - | - | - | 280.5% | 357.1% | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -23.5% | - | -17.4% | -18.1% | -17.5% | - | -10.8% | -11.6% | -11.5% | - |
| Return on equity | -29.0% | - | -22.2% | -24.5% | -25.7% | - | -13.7% | -15.6% | -15.1% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 9.65 | 11.36 | 8.70 | 6.07 | 4.73 | 4.29 | 7.91 | 5.84 | 7.87 | 9.90 |
| Quick ratio | 9.65 | 11.36 | 8.70 | 6.07 | 4.73 | 4.29 | 7.91 | 5.84 | 7.87 | 9.90 |
| Cash ratio | 5.54 | 7.30 | 5.53 | 4.13 | 2.65 | 2.36 | 4.65 | 3.41 | 3.05 | 4.54 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -472.8x | - | -1299.6x | -757.6x | -585.1x | - | -937.0x | -538.3x | -470.3x | - |
| Equity multiplier | 1.24 | 1.21 | 1.27 | 1.35 | 1.47 | 1.47 | 1.26 | 1.35 | 1.31 | 1.25 |
| Liabilities / Assets | 0.19 | 0.17 | 0.22 | 0.26 | 0.32 | 0.32 | 0.21 | 0.26 | 0.24 | 0.20 |
| Efficiency | ||||||||||
| Asset turnover | 0.00 | - | 0.00 | 0.00 | 0.00 | - | 0.00 | 0.00 | 0.00 | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 0.9x | - | 1.3x | 0.8x | 1.3x | - | 0.7x | 0.5x | 1.1x | - |
| P / S | 273.8x | - | 357.2x | 219.5x | 291.1x | - | 262.5x | 169.4x | 310.1x | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 0.0% | - | 0.0% | 0.0% | 0.0% | - | 0.0% | 0.0% | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | -35.8% | -27.6% | - |
| Revenue CAGR (5y) | -17.6% | - | 2.1% | 52.1% | 127.8% | - | 132.0% | - | - | - |
| Gross profit growth (YoY) | - | - | - | 0.0% | 0.0% | - | 0.0% | 0.0% | 0.0% | - |
| Operating income growth (YoY) | -45.7% | - | -14.0% | -24.5% | -24.4% | - | -30.6% | 10.1% | -9.5% | - |
| Net income growth (YoY) | -59.7% | - | -19.6% | -29.2% | -28.7% | - | -40.7% | 8.0% | 11.6% | - |
| EPS growth (YoY) | 47.8% | - | 45.5% | 38.7% | 17.9% | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 41.7% | 25.3% | -26.1% | -17.5% | -24.2% | -18.5% | -9.5% | -28.2% | -44.0% | -40.3% |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Silo Pharma against the 5 most active filers in the same SIC group.